FDA approves AbbVie therapy for Parkinson's disease
The US Food and Drug Administration has approved AbbVie's therapy for adults with Parkinson's disease, according to the agency's website.
The front page of AI-driven biology
Thursday, October 15, 2026Thu, Oct 15
Updated 6:32 PM PT
The US Food and Drug Administration has approved AbbVie's therapy for adults with Parkinson's disease, according to the agency's website.
Merck and Daiichi Sankyo have voluntarily withdrawn their application to the FDA for accelerated approval of their experimental lung cancer therapy, patritumab deruxtecan.
Viatris unit Mylan has filed a federal lawsuit in Delaware seeking a court ruling that its proposed generic version of semaglutide, sold by Novo Nordisk as the obesity injection Wegovy, does not infringe Novo's patents.
The US Food and Drug Administration has approved Mirum Pharmaceuticals' therapy to treat a rare bone condition.
ADARx Pharmaceuticals raised $446.3 million in gross proceeds, reported as $446 million by Fierce Biotech, by pricing an upsized offering of 26.3 million shares at $17 each alongside a separate $100 million private placement from AbbVie.
The FDA has expanded the approval of belzutifan (Welireg), Merck's oral HIF-2alpha inhibitor, into second-line therapy for kidney cancer.
Researchers at the University of Otago have developed phage Tn-seq, a platform that pairs transposon insertion sequencing with CRISPR and anti-CRISPR selection to systematically identify essential genes across diverse bacteriophages.
Novo Nordisk has acquired exclusive rights to Nanexa's PharmaShell drug delivery technology for up to five peptide programs across obesity, type 2 diabetes, and other cardiometabolic indications, in an agreement valued at up to €1.165 billion ($1.33 billion, reported as $1.3 billion elsewhere).
Genentech is paying $55 million upfront in a multi-target oncology collaboration that could exceed $1.5 billion with development, regulatory, and commercial milestones.
A hybrid computational framework called DEFT couples protein language models with 3D structural alignment to predict precise four-digit Enzyme Commission functional numbers.
Researchers trained a deep learning model to classify antibiotic mechanisms of action directly from high-throughput microscopy images of Corynebacterium glutamicum, a surrogate for Mycobacterium tuberculosis.
Researchers developed a machine-learning classifier that analyzes label-free optical microscopy images of surgical tissue margins to predict where glioblastoma tumors will recur.
Researchers used the generative protein-design model RFdiffusion alongside affinity maturation to create artificial proteins that selectively bind unanchored ubiquitin, an elusive signaling molecule lacking high-affinity probes.
Researchers combined cryo-electron tomography with computational structure prediction and integrative modeling to map a complete bacterial protein-translocation complex inside Mycoplasma pneumoniae cells at sub-nanometer resolution.
ProteoScopeR is an open-source R package and Shiny web tool designed to run reproducible method comparisons across quantitative mass spectrometry datasets.
General protein language models such as ESM-2 and ProtGPT2 fail to separate true T-cell receptor binders from synthetic negative controls, according to a benchmark evaluation.
Researchers applied single-cell RNA sequencing to Pseudomonas aeruginosa during phage infection to track how viral gene expression unfolds inside individual bacterial cells.
Researchers combined the dimension-reduction tool iNETgrate with harmonic persistent homology, a mathematical method that maps the shape of complex data, to rank disease-relevant genes across gene expression and DNA methylation layers.
Researchers built fastACCORD, a GPU-accelerated statistical framework that computes partial correlation networks across more than 300,000 multi-omic molecular features at once.
An automated modeling pipeline uses biophysical simulations of neurons to identify how adjusting normal ion channels can restore healthy firing patterns without directly targeting the mutated channel.
Researchers at the Helmholtz Center Munich built Crecerelle, a variational autoencoder that combines gene expression and alternative RNA splicing data to classify single cells.